[1] Biondi B, Cooper DS.  Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer[J]. Thyroid, 2010, 20(2): 135-146.   doi: 10.1089/thy.2009.0311
[2] Murphy E, Williams GR.  The thyroid and the skeleton[J]. Clin Endocrinol(Oxf), 2004, 61(3): 285-298.   doi: 10.1111/j.1365-2265.2004.02053.x
[3] Flynn RW, Bonellie SR, Jung RT, et al.  Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy[J]. J Clin Endocrinol Metab, 2010, 95(1): 186-193.   doi: 10.1210/jc.2009-1625
[4] Sun J, Yao L, Fang Y, et al.  Relationship between Subclinical Thyroid Risk of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies[J]. Int J Endocrinol, 2017, 2017: 8130796-.   doi: 10.1155/2017/8130796
[5] 陈志良, 李瑞平, 陈国豪, 等.  TSH抑制治疗对老年甲状腺癌术后骨代谢相关指标的影响[J]. 现代医院, 2017, 17(2): 241-244.   doi: 10.3969/j.issn.1671-332X.2017.02.029
Chen ZL, Li RP, Chen GH, et al.  Effect on Bone Metabolism Related Indexes in Elderly Patients with Thyroid Cancer after TSH Suppressive Therapy[J]. Morden Hosp, 2017, 17(2): 241-244.   doi: 10.3969/j.issn.1671-332X.2017.02.029
[6] 唐润薇.  抑制剂量的甲状腺激素对40例分化型甲状腺癌患者骨生化和骨密度的影响[J]. 药物评价研究, 2016, 39(5): 814-817.   doi: 10.7501/j.issn.1674-6376.2016.05.021
Tang RW.  Effect of thyroid stimulating hormone with inhibiting dose on bone biochemical and bone mineral density in 40 cases of postoperative patients with differentiated thyroid carcinoma[J]. Drug Evaluation Research, 2016, 39(5): 814-817.   doi: 10.7501/j.issn.1674-6376.2016.05.021
[7] Kung AW, Lorentz T, Tam SC.  Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women[J]. Clin Endocrinol(Oxf), 1993, 39(5): 535-540.   doi: 10.1111/j.1365-2265.1993.tb02405.x
[8] Giannini S, Nobile M, Sartori L, et al.  Bone density and mineral metabolism in thyroidectomized patients treated with long-term L-thyroxine[J]. Clin Sci(Lond), 1994, 87(5): 593-597.   doi: 10.1042/cs0870593
[9] Reverter JL, Colomé E, Holgado S, et al.  Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma[J]. Endocrine, 2010, 37(3): 467-472.   doi: 10.1007/s12020-010-9339-z
[10] Schneider R, Schneider M, Reiners C, et al.  Effects of levothyroxine on bone mineral density, muscle force, and bone turnover markers: a cohort study[J]. J Clin Endocrinol Metab, 2012, 97(11): 3926-3934.   doi: 10.1210/jc.2012-2570
[11] Reverter JL, Holgado S, Alonso N, et al.  Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma[J]. Endocr Relat Cancer, 2005, 12(4): 973-981.   doi: 10.1677/erc.1.01072
[12] Toivonen J, Tähtelä R, Laitinen K, et al.  Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy[J]. Eur J Endocrinol, 1998, 138(6): 667-673.   doi: 10.1530/eje.0.1380667
[13] Müller CG, Bayley TA, Harrison JE, et al.  Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance[J]. Thyroid, 1995, 5(2): 81-87.   doi: 10.1089/thy.1995.5.81
[14] Hawkins F, Rigopoulou D, Papapietro K, et al.  Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis[J]. Calcif Tissue Int, 1994, 54(1): 16-19.   doi: 10.1007/BF00316283
[15] Mendonça Monteiro de Barros G, Madeira M, Vieira NL, et al.  Bone mineral density and bone microarchitecture after long-term suppressive levothyroxine treatment of differentiated thyroid carcinoma in young adult patients[J]. J Bone Miner Metab, 2016, 34(4): 417-421.   doi: 10.1007/s00774-015-0680-4
[16] Sajjinanont T, Rajchadara S, Sriassawaamorn N, et al.  The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women[J]. J Med Assoc Thai, 2005, 88(Suppl 3): S71-76.
[17]

王勤甫, 赵顺林, 相开放, 等. 采用TSH抑制疗法对分化型甲状腺癌患者术后骨密度及骨代谢标志物的影响[J/OL]. 临床检验杂志(电子版), 2016, 5(4): 199−201[2018−06−03]. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=lcjyzz-d201604005.

Wang QF, Zhao SL, Xiang KF, et al. Effects of TSH inhibition on bone mineral density and bone metabolic markers in patients with differentiated thyroid cancer[J/OL]. Clin Lab J (Electr Edit), 2016, 5(4): 199−201 [2018−06−03]. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=lcjyzz-d201604005.
[18] Eftekhari M, Asadollahi A, Beiki D, et al.  The long term effect of levothyroxine on bone mineral density in patients with well differentiated thyroid carcinoma after treatment[J]. Hell J Nucl Med, 2008, 11(3): 160-163.
[19] 中华医学会核医学分会.  131I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志, 2014, 34(4): 264-278.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.002
Chinese Society of Nuclear Medicine.  Clinical guidelines for 131I therapy of differentiated thyroid cancer[J]. Chin J Nucl Med Mol Imaging, 2014, 34(4): 264-278.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.002
[20] Cooper DS, Doherty GM, Haugen BR, et al.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2006, 16(2): 109-142.   doi: 10.1089/thy.2006.16.109
[21] 杜娜, 王忠超, 盛琦, 等.  分化型甲状腺癌患者停用甲状腺激素后血脂与甲状腺功能的相关性分析[J]. 中华内分泌代谢杂志, 2016, 32(2): 112-116.   doi: 10.3760/cma.j.issn.1000-6699.2016.02.006
Du N, Wang ZC, Sheng Q, et al.  Relationship between serum lipid profile and thyroid function after thyroid hormone withdrawal in patients with differentiated thyroid carcinoma[J]. Chin J Endocrinol Metab, 2016, 32(2): 112-116.   doi: 10.3760/cma.j.issn.1000-6699.2016.02.006
[22] Haugen BR, Alexander EK, Bible KC, et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1): 1-133.   doi: 10.1089/thy.2015.0020
[23] Pacini F, Schlumberger M, Dralle H, et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium[J]. Eur J Endocrinol, 2006, 154(6): 787-803.   doi: 10.1530/eje.1.02158
[24] 中华医学会核医学分会.  甲状腺结节和分化型甲状腺癌诊治指南[J]. 中华核医学与分子影像杂志, 2013, 33(2): 96-115.   doi: 10.3760/cma.j.issn.2095-2848.2013.02.003
Chinese Society of Nuclear Medicine.  Clinical guidelines for the diagnosis and management of thyroid nodules and differentiated thyroid cancer[J]. Chin J Nucl Med Mol Imaging, 2013, 33(2): 96-115.   doi: 10.3760/cma.j.issn.2095-2848.2013.02.003
[25] 赵咏桔.  分化型甲状腺癌的个体化TSH抑制治疗: 双风险评估治疗目标[J]. 外科理论与实践, 2014, 19(3): 208-213.   doi: 10.3969/j.issn.1007-9610.2014.03.007
Zhao YJ.  Individualized TSH suppression therapy for differentiated thyroid carcinoma: A dual risk assessment of treatment objectives[J]. J Surg Concepts Pract, 2014, 19(3): 208-213.   doi: 10.3969/j.issn.1007-9610.2014.03.007
[26] Tournis S, Antoniou JD, Liakou CG, et al.  Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression[J]. Clin Endocrinol (Oxf), 2015, 82(2): 197-204.   doi: 10.1111/cen.12560
[27] Cardoso LF, Maciel LM, Paula FJ.  The multiple effects of thyroid disorders on bone and mineral metabolism[J]. Arq Bras Endocrinol Metabol, 2014, 58(5): 452-463.   doi: 10.1590/0004-2730000003311
[28] Lee MY, Park JH, Bae KS, et al.  Bone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancer[J]. Ann Surg Treat Res, 2014, 86(2): 55-60.   doi: 10.4174/astr.2014.86.2.55
[29] de Melo TG, da Assumpção LV, Santos Ade O, et al.  Low BMI and low TSH value as risk factors related to lower bone mineral density in postmenospausal women under levothyroxine therapy for differentiated thyroid carcinoma[J]. Thyroid Res, 2015, 8: 7-.   doi: 10.1186/s13044-015-0019-1
[30] 霍艳雷, 王丹阳, 吴书其, 等.  TSH抑制治疗对绝经后分化型甲状腺癌患者骨密度的影响[J]. 中华核医学与分子影像杂志, 2017, 37(4): 212-215.   doi: 10.3760/cma.j.issn.2095-2848.2017.04.005
Huo YL, Wang DY, Wu SQ, et al.  Effect of postoperative thyrotropin suppression on bone mineral density in postmenopausal women with differentiated thyroid carcinoma[J]. Chin J Nucl Med Mol Imaging, 2017, 37(4): 212-215.   doi: 10.3760/cma.j.issn.2095-2848.2017.04.005
[31] 王玉, 贺亮, 蒋森, 等.  分化型甲状腺癌患者术后TSH抑制治疗对骨密度影响的前瞻性研究[J]. 中国骨质疏松杂志, 2016, 22(1): 76-82.   doi: 10.3969/j.issn.1006-7108.2016.01.016
Wang Y, He L, Jiang S, et al.  The effect of TSH suppressive therapy for differentiated thyroid carcinoma on bone mineral density: a prospective study[J]. Chin J Osteoporosis, 2016, 22(1): 76-82.   doi: 10.3969/j.issn.1006-7108.2016.01.016
[32] 张译徽, 郭辉, 朱新生.  腰椎松质骨CT值与年龄、双能X线骨密度值相关性研究[J]. 中国骨质疏松杂志, 2016, 22(6): 695-699.   doi: 10.3969/j.issn.1006-7108.2016.06.008
Zhang YH, Guo H, Zhu XS.  Correlation among CT attenuation value of cancellous bone in the lumbar vertebrae, age, and bone mineral density measured by dual-energy X-ray absorptiometry[J]. Chin J Osteoporo, 2016, 22(6): 695-699.   doi: 10.3969/j.issn.1006-7108.2016.06.008
[33] 申才良, 刘斌, 唐天驷, 等.  冷冻、冻干、辐照对用于脊柱融合的胫骨皮质骨力学性能的影响[J]. 医用生物力学, 2016, 31(1): 61-66.   doi: 10.3871/j.1004-7220.2016.01.061
Shen CL, Liu B, Tang TS, et al.  Effects from deep-freezing, freeze-drying or radiation on mechanical properties of cortical bone for spinal fusion[J]. J Med Biomechanics, 2016, 31(1): 61-66.   doi: 10.3871/j.1004-7220.2016.01.061
[34] Ma R, Latif R, Davies TF.  Thyrotropin-independent induction of thyroid endoderm from embryonic stem cells by activin A[J]. Endocrinology, 2009, 150(4): 1970-1975.   doi: 10.1210/en.2008-1374
[35] Abe E, Marians RC, Wang QY, et al.  TSH is a negative regulator of skeletal remodeling[J]. Cell, 2003, 115(2): 151-162.   doi: 10.1016/s0092-8674(03)00771-2
[36] 孙蕴, 贺丽英, 马兆坤, 等.  Ward三角区再研究[J]. 中国骨质疏松杂志, 2016, 22(6): 706-710, 717.   doi: 10.3969/j.issn.1006-7108.2016.06.010
Sun Y, He LY, Ma ZK, et al.  Further study on the Ward's triangle region[J]. Chin J Osteoporosis, 2016, 22(6): 706-710, 717.   doi: 10.3969/j.issn.1006-7108.2016.06.010